SEOM clinical guideline on heritable TP53-related cancer syndrome (2022)
Abstract Li-Fraumeni syndrome is caused by heterozygous germline pathogenic variants in the TP53 gene. It involves a high risk of a variety of malignant tumors in childhood and adulthood, the main ones being premenopausal breast cancer, soft tissue sarcomas and osteosarcomas, central nervous system...
Ausführliche Beschreibung
Autor*in: |
Sánchez-Heras, Ana Beatriz [verfasserIn] |
---|
Format: |
E-Artikel |
---|---|
Sprache: |
Englisch |
Erschienen: |
2023 |
---|
Schlagwörter: |
---|
Anmerkung: |
© The Author(s) 2023 |
---|
Übergeordnetes Werk: |
Enthalten in: Revista de oncología - Barcelona : Doyma, 2000, 25(2023), 9 vom: 03. Mai, Seite 2627-2633 |
---|---|
Übergeordnetes Werk: |
volume:25 ; year:2023 ; number:9 ; day:03 ; month:05 ; pages:2627-2633 |
Links: |
---|
DOI / URN: |
10.1007/s12094-023-03202-9 |
---|
Katalog-ID: |
SPR052742571 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | SPR052742571 | ||
003 | DE-627 | ||
005 | 20230815064740.0 | ||
007 | cr uuu---uuuuu | ||
008 | 230815s2023 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1007/s12094-023-03202-9 |2 doi | |
035 | |a (DE-627)SPR052742571 | ||
035 | |a (SPR)s12094-023-03202-9-e | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Sánchez-Heras, Ana Beatriz |e verfasserin |0 (orcid)0000-0003-1742-5374 |4 aut | |
245 | 1 | 0 | |a SEOM clinical guideline on heritable TP53-related cancer syndrome (2022) |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
500 | |a © The Author(s) 2023 | ||
520 | |a Abstract Li-Fraumeni syndrome is caused by heterozygous germline pathogenic variants in the TP53 gene. It involves a high risk of a variety of malignant tumors in childhood and adulthood, the main ones being premenopausal breast cancer, soft tissue sarcomas and osteosarcomas, central nervous system tumors, and adrenocortical carcinomas. The variability of the associated clinical manifestations, which do not always fit the classic criteria of Li-Fraumeni syndrome, has led the concept of SLF to extend to a more overarching cancer predisposition syndrome, termed hereditable TP53-related cancer syndrome (hTP53rc). However, prospective studies are needed to assess genotype–phenotype characteristics, as well as to evaluate and validate risk-adjusted recommendations. This guideline aims to establish the basis for interpreting pathogenic variants in the TP53 gene and provide recommendations for effective screening and prevention of associated cancers in carrier individuals. | ||
650 | 4 | |a Li-Fraumeni syndrome |7 (dpeaa)DE-He213 | |
650 | 4 | |a Cancer |7 (dpeaa)DE-He213 | |
650 | 4 | |a Pathogenic variants |7 (dpeaa)DE-He213 | |
700 | 1 | |a Ramon y Cajal, Teresa |0 (orcid)0000-0003-3490-3585 |4 aut | |
700 | 1 | |a Pineda, Marta |0 (orcid)0000-0002-5403-5845 |4 aut | |
700 | 1 | |a Aguirre, Elena |0 (orcid)0000-0002-2999-5959 |4 aut | |
700 | 1 | |a Graña, Begoña |0 (orcid)0000-0003-2008-8188 |4 aut | |
700 | 1 | |a Chirivella, Isabel |0 (orcid)0000-0002-0733-3276 |4 aut | |
700 | 1 | |a Balmaña, Judit |0 (orcid)0000-0002-0762-6415 |4 aut | |
700 | 1 | |a Brunet, Joan |0 (orcid)0000-0003-1945-3512 |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Revista de oncología |d Barcelona : Doyma, 2000 |g 25(2023), 9 vom: 03. Mai, Seite 2627-2633 |w (DE-627)385985452 |w (DE-600)2143451-7 |x 1578-195X |7 nnns |
773 | 1 | 8 | |g volume:25 |g year:2023 |g number:9 |g day:03 |g month:05 |g pages:2627-2633 |
856 | 4 | 0 | |u https://dx.doi.org/10.1007/s12094-023-03202-9 |z kostenfrei |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a SYSFLAG_A | ||
912 | |a GBV_SPRINGER | ||
912 | |a GBV_ILN_20 | ||
912 | |a GBV_ILN_22 | ||
912 | |a GBV_ILN_23 | ||
912 | |a GBV_ILN_24 | ||
912 | |a GBV_ILN_31 | ||
912 | |a GBV_ILN_39 | ||
912 | |a GBV_ILN_40 | ||
912 | |a GBV_ILN_60 | ||
912 | |a GBV_ILN_62 | ||
912 | |a GBV_ILN_65 | ||
912 | |a GBV_ILN_69 | ||
912 | |a GBV_ILN_70 | ||
912 | |a GBV_ILN_73 | ||
912 | |a GBV_ILN_74 | ||
912 | |a GBV_ILN_90 | ||
912 | |a GBV_ILN_95 | ||
912 | |a GBV_ILN_100 | ||
912 | |a GBV_ILN_105 | ||
912 | |a GBV_ILN_120 | ||
912 | |a GBV_ILN_152 | ||
912 | |a GBV_ILN_161 | ||
912 | |a GBV_ILN_171 | ||
912 | |a GBV_ILN_187 | ||
912 | |a GBV_ILN_224 | ||
912 | |a GBV_ILN_250 | ||
912 | |a GBV_ILN_281 | ||
912 | |a GBV_ILN_285 | ||
912 | |a GBV_ILN_293 | ||
912 | |a GBV_ILN_370 | ||
912 | |a GBV_ILN_602 | ||
912 | |a GBV_ILN_702 | ||
951 | |a AR | ||
952 | |d 25 |j 2023 |e 9 |b 03 |c 05 |h 2627-2633 |
author_variant |
a b s h abs absh y c t r yct yctr m p mp e a ea b g bg i c ic j b jb j b jb |
---|---|
matchkey_str |
article:1578195X:2023----::emlncludlnohrtbep3eaec |
hierarchy_sort_str |
2023 |
publishDate |
2023 |
allfields |
10.1007/s12094-023-03202-9 doi (DE-627)SPR052742571 (SPR)s12094-023-03202-9-e DE-627 ger DE-627 rakwb eng Sánchez-Heras, Ana Beatriz verfasserin (orcid)0000-0003-1742-5374 aut SEOM clinical guideline on heritable TP53-related cancer syndrome (2022) 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Author(s) 2023 Abstract Li-Fraumeni syndrome is caused by heterozygous germline pathogenic variants in the TP53 gene. It involves a high risk of a variety of malignant tumors in childhood and adulthood, the main ones being premenopausal breast cancer, soft tissue sarcomas and osteosarcomas, central nervous system tumors, and adrenocortical carcinomas. The variability of the associated clinical manifestations, which do not always fit the classic criteria of Li-Fraumeni syndrome, has led the concept of SLF to extend to a more overarching cancer predisposition syndrome, termed hereditable TP53-related cancer syndrome (hTP53rc). However, prospective studies are needed to assess genotype–phenotype characteristics, as well as to evaluate and validate risk-adjusted recommendations. This guideline aims to establish the basis for interpreting pathogenic variants in the TP53 gene and provide recommendations for effective screening and prevention of associated cancers in carrier individuals. Li-Fraumeni syndrome (dpeaa)DE-He213 Cancer (dpeaa)DE-He213 Pathogenic variants (dpeaa)DE-He213 Ramon y Cajal, Teresa (orcid)0000-0003-3490-3585 aut Pineda, Marta (orcid)0000-0002-5403-5845 aut Aguirre, Elena (orcid)0000-0002-2999-5959 aut Graña, Begoña (orcid)0000-0003-2008-8188 aut Chirivella, Isabel (orcid)0000-0002-0733-3276 aut Balmaña, Judit (orcid)0000-0002-0762-6415 aut Brunet, Joan (orcid)0000-0003-1945-3512 aut Enthalten in Revista de oncología Barcelona : Doyma, 2000 25(2023), 9 vom: 03. Mai, Seite 2627-2633 (DE-627)385985452 (DE-600)2143451-7 1578-195X nnns volume:25 year:2023 number:9 day:03 month:05 pages:2627-2633 https://dx.doi.org/10.1007/s12094-023-03202-9 kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_120 GBV_ILN_152 GBV_ILN_161 GBV_ILN_171 GBV_ILN_187 GBV_ILN_224 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 AR 25 2023 9 03 05 2627-2633 |
spelling |
10.1007/s12094-023-03202-9 doi (DE-627)SPR052742571 (SPR)s12094-023-03202-9-e DE-627 ger DE-627 rakwb eng Sánchez-Heras, Ana Beatriz verfasserin (orcid)0000-0003-1742-5374 aut SEOM clinical guideline on heritable TP53-related cancer syndrome (2022) 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Author(s) 2023 Abstract Li-Fraumeni syndrome is caused by heterozygous germline pathogenic variants in the TP53 gene. It involves a high risk of a variety of malignant tumors in childhood and adulthood, the main ones being premenopausal breast cancer, soft tissue sarcomas and osteosarcomas, central nervous system tumors, and adrenocortical carcinomas. The variability of the associated clinical manifestations, which do not always fit the classic criteria of Li-Fraumeni syndrome, has led the concept of SLF to extend to a more overarching cancer predisposition syndrome, termed hereditable TP53-related cancer syndrome (hTP53rc). However, prospective studies are needed to assess genotype–phenotype characteristics, as well as to evaluate and validate risk-adjusted recommendations. This guideline aims to establish the basis for interpreting pathogenic variants in the TP53 gene and provide recommendations for effective screening and prevention of associated cancers in carrier individuals. Li-Fraumeni syndrome (dpeaa)DE-He213 Cancer (dpeaa)DE-He213 Pathogenic variants (dpeaa)DE-He213 Ramon y Cajal, Teresa (orcid)0000-0003-3490-3585 aut Pineda, Marta (orcid)0000-0002-5403-5845 aut Aguirre, Elena (orcid)0000-0002-2999-5959 aut Graña, Begoña (orcid)0000-0003-2008-8188 aut Chirivella, Isabel (orcid)0000-0002-0733-3276 aut Balmaña, Judit (orcid)0000-0002-0762-6415 aut Brunet, Joan (orcid)0000-0003-1945-3512 aut Enthalten in Revista de oncología Barcelona : Doyma, 2000 25(2023), 9 vom: 03. Mai, Seite 2627-2633 (DE-627)385985452 (DE-600)2143451-7 1578-195X nnns volume:25 year:2023 number:9 day:03 month:05 pages:2627-2633 https://dx.doi.org/10.1007/s12094-023-03202-9 kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_120 GBV_ILN_152 GBV_ILN_161 GBV_ILN_171 GBV_ILN_187 GBV_ILN_224 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 AR 25 2023 9 03 05 2627-2633 |
allfields_unstemmed |
10.1007/s12094-023-03202-9 doi (DE-627)SPR052742571 (SPR)s12094-023-03202-9-e DE-627 ger DE-627 rakwb eng Sánchez-Heras, Ana Beatriz verfasserin (orcid)0000-0003-1742-5374 aut SEOM clinical guideline on heritable TP53-related cancer syndrome (2022) 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Author(s) 2023 Abstract Li-Fraumeni syndrome is caused by heterozygous germline pathogenic variants in the TP53 gene. It involves a high risk of a variety of malignant tumors in childhood and adulthood, the main ones being premenopausal breast cancer, soft tissue sarcomas and osteosarcomas, central nervous system tumors, and adrenocortical carcinomas. The variability of the associated clinical manifestations, which do not always fit the classic criteria of Li-Fraumeni syndrome, has led the concept of SLF to extend to a more overarching cancer predisposition syndrome, termed hereditable TP53-related cancer syndrome (hTP53rc). However, prospective studies are needed to assess genotype–phenotype characteristics, as well as to evaluate and validate risk-adjusted recommendations. This guideline aims to establish the basis for interpreting pathogenic variants in the TP53 gene and provide recommendations for effective screening and prevention of associated cancers in carrier individuals. Li-Fraumeni syndrome (dpeaa)DE-He213 Cancer (dpeaa)DE-He213 Pathogenic variants (dpeaa)DE-He213 Ramon y Cajal, Teresa (orcid)0000-0003-3490-3585 aut Pineda, Marta (orcid)0000-0002-5403-5845 aut Aguirre, Elena (orcid)0000-0002-2999-5959 aut Graña, Begoña (orcid)0000-0003-2008-8188 aut Chirivella, Isabel (orcid)0000-0002-0733-3276 aut Balmaña, Judit (orcid)0000-0002-0762-6415 aut Brunet, Joan (orcid)0000-0003-1945-3512 aut Enthalten in Revista de oncología Barcelona : Doyma, 2000 25(2023), 9 vom: 03. Mai, Seite 2627-2633 (DE-627)385985452 (DE-600)2143451-7 1578-195X nnns volume:25 year:2023 number:9 day:03 month:05 pages:2627-2633 https://dx.doi.org/10.1007/s12094-023-03202-9 kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_120 GBV_ILN_152 GBV_ILN_161 GBV_ILN_171 GBV_ILN_187 GBV_ILN_224 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 AR 25 2023 9 03 05 2627-2633 |
allfieldsGer |
10.1007/s12094-023-03202-9 doi (DE-627)SPR052742571 (SPR)s12094-023-03202-9-e DE-627 ger DE-627 rakwb eng Sánchez-Heras, Ana Beatriz verfasserin (orcid)0000-0003-1742-5374 aut SEOM clinical guideline on heritable TP53-related cancer syndrome (2022) 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Author(s) 2023 Abstract Li-Fraumeni syndrome is caused by heterozygous germline pathogenic variants in the TP53 gene. It involves a high risk of a variety of malignant tumors in childhood and adulthood, the main ones being premenopausal breast cancer, soft tissue sarcomas and osteosarcomas, central nervous system tumors, and adrenocortical carcinomas. The variability of the associated clinical manifestations, which do not always fit the classic criteria of Li-Fraumeni syndrome, has led the concept of SLF to extend to a more overarching cancer predisposition syndrome, termed hereditable TP53-related cancer syndrome (hTP53rc). However, prospective studies are needed to assess genotype–phenotype characteristics, as well as to evaluate and validate risk-adjusted recommendations. This guideline aims to establish the basis for interpreting pathogenic variants in the TP53 gene and provide recommendations for effective screening and prevention of associated cancers in carrier individuals. Li-Fraumeni syndrome (dpeaa)DE-He213 Cancer (dpeaa)DE-He213 Pathogenic variants (dpeaa)DE-He213 Ramon y Cajal, Teresa (orcid)0000-0003-3490-3585 aut Pineda, Marta (orcid)0000-0002-5403-5845 aut Aguirre, Elena (orcid)0000-0002-2999-5959 aut Graña, Begoña (orcid)0000-0003-2008-8188 aut Chirivella, Isabel (orcid)0000-0002-0733-3276 aut Balmaña, Judit (orcid)0000-0002-0762-6415 aut Brunet, Joan (orcid)0000-0003-1945-3512 aut Enthalten in Revista de oncología Barcelona : Doyma, 2000 25(2023), 9 vom: 03. Mai, Seite 2627-2633 (DE-627)385985452 (DE-600)2143451-7 1578-195X nnns volume:25 year:2023 number:9 day:03 month:05 pages:2627-2633 https://dx.doi.org/10.1007/s12094-023-03202-9 kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_120 GBV_ILN_152 GBV_ILN_161 GBV_ILN_171 GBV_ILN_187 GBV_ILN_224 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 AR 25 2023 9 03 05 2627-2633 |
allfieldsSound |
10.1007/s12094-023-03202-9 doi (DE-627)SPR052742571 (SPR)s12094-023-03202-9-e DE-627 ger DE-627 rakwb eng Sánchez-Heras, Ana Beatriz verfasserin (orcid)0000-0003-1742-5374 aut SEOM clinical guideline on heritable TP53-related cancer syndrome (2022) 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Author(s) 2023 Abstract Li-Fraumeni syndrome is caused by heterozygous germline pathogenic variants in the TP53 gene. It involves a high risk of a variety of malignant tumors in childhood and adulthood, the main ones being premenopausal breast cancer, soft tissue sarcomas and osteosarcomas, central nervous system tumors, and adrenocortical carcinomas. The variability of the associated clinical manifestations, which do not always fit the classic criteria of Li-Fraumeni syndrome, has led the concept of SLF to extend to a more overarching cancer predisposition syndrome, termed hereditable TP53-related cancer syndrome (hTP53rc). However, prospective studies are needed to assess genotype–phenotype characteristics, as well as to evaluate and validate risk-adjusted recommendations. This guideline aims to establish the basis for interpreting pathogenic variants in the TP53 gene and provide recommendations for effective screening and prevention of associated cancers in carrier individuals. Li-Fraumeni syndrome (dpeaa)DE-He213 Cancer (dpeaa)DE-He213 Pathogenic variants (dpeaa)DE-He213 Ramon y Cajal, Teresa (orcid)0000-0003-3490-3585 aut Pineda, Marta (orcid)0000-0002-5403-5845 aut Aguirre, Elena (orcid)0000-0002-2999-5959 aut Graña, Begoña (orcid)0000-0003-2008-8188 aut Chirivella, Isabel (orcid)0000-0002-0733-3276 aut Balmaña, Judit (orcid)0000-0002-0762-6415 aut Brunet, Joan (orcid)0000-0003-1945-3512 aut Enthalten in Revista de oncología Barcelona : Doyma, 2000 25(2023), 9 vom: 03. Mai, Seite 2627-2633 (DE-627)385985452 (DE-600)2143451-7 1578-195X nnns volume:25 year:2023 number:9 day:03 month:05 pages:2627-2633 https://dx.doi.org/10.1007/s12094-023-03202-9 kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_120 GBV_ILN_152 GBV_ILN_161 GBV_ILN_171 GBV_ILN_187 GBV_ILN_224 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 AR 25 2023 9 03 05 2627-2633 |
language |
English |
source |
Enthalten in Revista de oncología 25(2023), 9 vom: 03. Mai, Seite 2627-2633 volume:25 year:2023 number:9 day:03 month:05 pages:2627-2633 |
sourceStr |
Enthalten in Revista de oncología 25(2023), 9 vom: 03. Mai, Seite 2627-2633 volume:25 year:2023 number:9 day:03 month:05 pages:2627-2633 |
format_phy_str_mv |
Article |
institution |
findex.gbv.de |
topic_facet |
Li-Fraumeni syndrome Cancer Pathogenic variants |
isfreeaccess_bool |
true |
container_title |
Revista de oncología |
authorswithroles_txt_mv |
Sánchez-Heras, Ana Beatriz @@aut@@ Ramon y Cajal, Teresa @@aut@@ Pineda, Marta @@aut@@ Aguirre, Elena @@aut@@ Graña, Begoña @@aut@@ Chirivella, Isabel @@aut@@ Balmaña, Judit @@aut@@ Brunet, Joan @@aut@@ |
publishDateDaySort_date |
2023-05-03T00:00:00Z |
hierarchy_top_id |
385985452 |
id |
SPR052742571 |
language_de |
englisch |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000naa a22002652 4500</leader><controlfield tag="001">SPR052742571</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230815064740.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230815s2023 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s12094-023-03202-9</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR052742571</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s12094-023-03202-9-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Sánchez-Heras, Ana Beatriz</subfield><subfield code="e">verfasserin</subfield><subfield code="0">(orcid)0000-0003-1742-5374</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">SEOM clinical guideline on heritable TP53-related cancer syndrome (2022)</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2023</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© The Author(s) 2023</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract Li-Fraumeni syndrome is caused by heterozygous germline pathogenic variants in the TP53 gene. It involves a high risk of a variety of malignant tumors in childhood and adulthood, the main ones being premenopausal breast cancer, soft tissue sarcomas and osteosarcomas, central nervous system tumors, and adrenocortical carcinomas. The variability of the associated clinical manifestations, which do not always fit the classic criteria of Li-Fraumeni syndrome, has led the concept of SLF to extend to a more overarching cancer predisposition syndrome, termed hereditable TP53-related cancer syndrome (hTP53rc). However, prospective studies are needed to assess genotype–phenotype characteristics, as well as to evaluate and validate risk-adjusted recommendations. This guideline aims to establish the basis for interpreting pathogenic variants in the TP53 gene and provide recommendations for effective screening and prevention of associated cancers in carrier individuals.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Li-Fraumeni syndrome</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cancer</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pathogenic variants</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ramon y Cajal, Teresa</subfield><subfield code="0">(orcid)0000-0003-3490-3585</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Pineda, Marta</subfield><subfield code="0">(orcid)0000-0002-5403-5845</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Aguirre, Elena</subfield><subfield code="0">(orcid)0000-0002-2999-5959</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Graña, Begoña</subfield><subfield code="0">(orcid)0000-0003-2008-8188</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Chirivella, Isabel</subfield><subfield code="0">(orcid)0000-0002-0733-3276</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Balmaña, Judit</subfield><subfield code="0">(orcid)0000-0002-0762-6415</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Brunet, Joan</subfield><subfield code="0">(orcid)0000-0003-1945-3512</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Revista de oncología</subfield><subfield code="d">Barcelona : Doyma, 2000</subfield><subfield code="g">25(2023), 9 vom: 03. Mai, Seite 2627-2633</subfield><subfield code="w">(DE-627)385985452</subfield><subfield code="w">(DE-600)2143451-7</subfield><subfield code="x">1578-195X</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:25</subfield><subfield code="g">year:2023</subfield><subfield code="g">number:9</subfield><subfield code="g">day:03</subfield><subfield code="g">month:05</subfield><subfield code="g">pages:2627-2633</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s12094-023-03202-9</subfield><subfield code="z">kostenfrei</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_90</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_100</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_120</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_171</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_187</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_224</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_250</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_281</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_370</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">25</subfield><subfield code="j">2023</subfield><subfield code="e">9</subfield><subfield code="b">03</subfield><subfield code="c">05</subfield><subfield code="h">2627-2633</subfield></datafield></record></collection>
|
author |
Sánchez-Heras, Ana Beatriz |
spellingShingle |
Sánchez-Heras, Ana Beatriz misc Li-Fraumeni syndrome misc Cancer misc Pathogenic variants SEOM clinical guideline on heritable TP53-related cancer syndrome (2022) |
authorStr |
Sánchez-Heras, Ana Beatriz |
ppnlink_with_tag_str_mv |
@@773@@(DE-627)385985452 |
format |
electronic Article |
delete_txt_mv |
keep |
author_role |
aut aut aut aut aut aut aut aut |
collection |
springer |
remote_str |
true |
illustrated |
Not Illustrated |
issn |
1578-195X |
topic_title |
SEOM clinical guideline on heritable TP53-related cancer syndrome (2022) Li-Fraumeni syndrome (dpeaa)DE-He213 Cancer (dpeaa)DE-He213 Pathogenic variants (dpeaa)DE-He213 |
topic |
misc Li-Fraumeni syndrome misc Cancer misc Pathogenic variants |
topic_unstemmed |
misc Li-Fraumeni syndrome misc Cancer misc Pathogenic variants |
topic_browse |
misc Li-Fraumeni syndrome misc Cancer misc Pathogenic variants |
format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
format_main_str_mv |
Text Zeitschrift/Artikel |
carriertype_str_mv |
cr |
hierarchy_parent_title |
Revista de oncología |
hierarchy_parent_id |
385985452 |
hierarchy_top_title |
Revista de oncología |
isfreeaccess_txt |
true |
familylinks_str_mv |
(DE-627)385985452 (DE-600)2143451-7 |
title |
SEOM clinical guideline on heritable TP53-related cancer syndrome (2022) |
ctrlnum |
(DE-627)SPR052742571 (SPR)s12094-023-03202-9-e |
title_full |
SEOM clinical guideline on heritable TP53-related cancer syndrome (2022) |
author_sort |
Sánchez-Heras, Ana Beatriz |
journal |
Revista de oncología |
journalStr |
Revista de oncología |
lang_code |
eng |
isOA_bool |
true |
recordtype |
marc |
publishDateSort |
2023 |
contenttype_str_mv |
txt |
container_start_page |
2627 |
author_browse |
Sánchez-Heras, Ana Beatriz Ramon y Cajal, Teresa Pineda, Marta Aguirre, Elena Graña, Begoña Chirivella, Isabel Balmaña, Judit Brunet, Joan |
container_volume |
25 |
format_se |
Elektronische Aufsätze |
author-letter |
Sánchez-Heras, Ana Beatriz |
doi_str_mv |
10.1007/s12094-023-03202-9 |
normlink |
(ORCID)0000-0003-1742-5374 (ORCID)0000-0003-3490-3585 (ORCID)0000-0002-5403-5845 (ORCID)0000-0002-2999-5959 (ORCID)0000-0003-2008-8188 (ORCID)0000-0002-0733-3276 (ORCID)0000-0002-0762-6415 (ORCID)0000-0003-1945-3512 |
normlink_prefix_str_mv |
(orcid)0000-0003-1742-5374 (orcid)0000-0003-3490-3585 (orcid)0000-0002-5403-5845 (orcid)0000-0002-2999-5959 (orcid)0000-0003-2008-8188 (orcid)0000-0002-0733-3276 (orcid)0000-0002-0762-6415 (orcid)0000-0003-1945-3512 |
title_sort |
seom clinical guideline on heritable tp53-related cancer syndrome (2022) |
title_auth |
SEOM clinical guideline on heritable TP53-related cancer syndrome (2022) |
abstract |
Abstract Li-Fraumeni syndrome is caused by heterozygous germline pathogenic variants in the TP53 gene. It involves a high risk of a variety of malignant tumors in childhood and adulthood, the main ones being premenopausal breast cancer, soft tissue sarcomas and osteosarcomas, central nervous system tumors, and adrenocortical carcinomas. The variability of the associated clinical manifestations, which do not always fit the classic criteria of Li-Fraumeni syndrome, has led the concept of SLF to extend to a more overarching cancer predisposition syndrome, termed hereditable TP53-related cancer syndrome (hTP53rc). However, prospective studies are needed to assess genotype–phenotype characteristics, as well as to evaluate and validate risk-adjusted recommendations. This guideline aims to establish the basis for interpreting pathogenic variants in the TP53 gene and provide recommendations for effective screening and prevention of associated cancers in carrier individuals. © The Author(s) 2023 |
abstractGer |
Abstract Li-Fraumeni syndrome is caused by heterozygous germline pathogenic variants in the TP53 gene. It involves a high risk of a variety of malignant tumors in childhood and adulthood, the main ones being premenopausal breast cancer, soft tissue sarcomas and osteosarcomas, central nervous system tumors, and adrenocortical carcinomas. The variability of the associated clinical manifestations, which do not always fit the classic criteria of Li-Fraumeni syndrome, has led the concept of SLF to extend to a more overarching cancer predisposition syndrome, termed hereditable TP53-related cancer syndrome (hTP53rc). However, prospective studies are needed to assess genotype–phenotype characteristics, as well as to evaluate and validate risk-adjusted recommendations. This guideline aims to establish the basis for interpreting pathogenic variants in the TP53 gene and provide recommendations for effective screening and prevention of associated cancers in carrier individuals. © The Author(s) 2023 |
abstract_unstemmed |
Abstract Li-Fraumeni syndrome is caused by heterozygous germline pathogenic variants in the TP53 gene. It involves a high risk of a variety of malignant tumors in childhood and adulthood, the main ones being premenopausal breast cancer, soft tissue sarcomas and osteosarcomas, central nervous system tumors, and adrenocortical carcinomas. The variability of the associated clinical manifestations, which do not always fit the classic criteria of Li-Fraumeni syndrome, has led the concept of SLF to extend to a more overarching cancer predisposition syndrome, termed hereditable TP53-related cancer syndrome (hTP53rc). However, prospective studies are needed to assess genotype–phenotype characteristics, as well as to evaluate and validate risk-adjusted recommendations. This guideline aims to establish the basis for interpreting pathogenic variants in the TP53 gene and provide recommendations for effective screening and prevention of associated cancers in carrier individuals. © The Author(s) 2023 |
collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_120 GBV_ILN_152 GBV_ILN_161 GBV_ILN_171 GBV_ILN_187 GBV_ILN_224 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 |
container_issue |
9 |
title_short |
SEOM clinical guideline on heritable TP53-related cancer syndrome (2022) |
url |
https://dx.doi.org/10.1007/s12094-023-03202-9 |
remote_bool |
true |
author2 |
Ramon y Cajal, Teresa Pineda, Marta Aguirre, Elena Graña, Begoña Chirivella, Isabel Balmaña, Judit Brunet, Joan |
author2Str |
Ramon y Cajal, Teresa Pineda, Marta Aguirre, Elena Graña, Begoña Chirivella, Isabel Balmaña, Judit Brunet, Joan |
ppnlink |
385985452 |
mediatype_str_mv |
c |
isOA_txt |
true |
hochschulschrift_bool |
false |
doi_str |
10.1007/s12094-023-03202-9 |
up_date |
2024-07-03T14:28:08.169Z |
_version_ |
1803568428533940224 |
fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000naa a22002652 4500</leader><controlfield tag="001">SPR052742571</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230815064740.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230815s2023 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s12094-023-03202-9</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR052742571</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s12094-023-03202-9-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Sánchez-Heras, Ana Beatriz</subfield><subfield code="e">verfasserin</subfield><subfield code="0">(orcid)0000-0003-1742-5374</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">SEOM clinical guideline on heritable TP53-related cancer syndrome (2022)</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2023</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© The Author(s) 2023</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract Li-Fraumeni syndrome is caused by heterozygous germline pathogenic variants in the TP53 gene. It involves a high risk of a variety of malignant tumors in childhood and adulthood, the main ones being premenopausal breast cancer, soft tissue sarcomas and osteosarcomas, central nervous system tumors, and adrenocortical carcinomas. The variability of the associated clinical manifestations, which do not always fit the classic criteria of Li-Fraumeni syndrome, has led the concept of SLF to extend to a more overarching cancer predisposition syndrome, termed hereditable TP53-related cancer syndrome (hTP53rc). However, prospective studies are needed to assess genotype–phenotype characteristics, as well as to evaluate and validate risk-adjusted recommendations. This guideline aims to establish the basis for interpreting pathogenic variants in the TP53 gene and provide recommendations for effective screening and prevention of associated cancers in carrier individuals.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Li-Fraumeni syndrome</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cancer</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pathogenic variants</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ramon y Cajal, Teresa</subfield><subfield code="0">(orcid)0000-0003-3490-3585</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Pineda, Marta</subfield><subfield code="0">(orcid)0000-0002-5403-5845</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Aguirre, Elena</subfield><subfield code="0">(orcid)0000-0002-2999-5959</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Graña, Begoña</subfield><subfield code="0">(orcid)0000-0003-2008-8188</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Chirivella, Isabel</subfield><subfield code="0">(orcid)0000-0002-0733-3276</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Balmaña, Judit</subfield><subfield code="0">(orcid)0000-0002-0762-6415</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Brunet, Joan</subfield><subfield code="0">(orcid)0000-0003-1945-3512</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Revista de oncología</subfield><subfield code="d">Barcelona : Doyma, 2000</subfield><subfield code="g">25(2023), 9 vom: 03. Mai, Seite 2627-2633</subfield><subfield code="w">(DE-627)385985452</subfield><subfield code="w">(DE-600)2143451-7</subfield><subfield code="x">1578-195X</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:25</subfield><subfield code="g">year:2023</subfield><subfield code="g">number:9</subfield><subfield code="g">day:03</subfield><subfield code="g">month:05</subfield><subfield code="g">pages:2627-2633</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s12094-023-03202-9</subfield><subfield code="z">kostenfrei</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_90</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_100</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_120</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_171</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_187</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_224</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_250</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_281</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_370</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">25</subfield><subfield code="j">2023</subfield><subfield code="e">9</subfield><subfield code="b">03</subfield><subfield code="c">05</subfield><subfield code="h">2627-2633</subfield></datafield></record></collection>
|
score |
7.399727 |